Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients

Journal of Experimental & Clinical Cancer Research

Grzegorz Mazur⁵  Kazimierz Kuliczkowski³  Andrzej Tukiendorf²  Dagmara Baczyńska¹  Justyna Rybka³  Aleksandra Butrym⁴ 

[1] Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Wroclaw, Poland;Department of Epidemiology, Cancer Center-Institute of Oncology, Gliwice, Poland;Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteur 4 Str, Wroclaw, 50-367, Poland;Department of Physiology, Wroclaw Medical University, Wroclaw, Poland;Department of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland

关键词: Prognosis;    Survival;    Expression;    Acute myeloid leukemia;    miR-204;   

Others  :  1220670
DOI  :  10.1186/s13046-015-0184-z

 received in 2015-04-01, accepted in 2015-06-24,  发布年份 2015

【 摘 要 】

Background

Acute myeloid leukemia (AML) is a heterogeneous neoplasm of the bone marrow with poor prognosis. In clinical practice new prognostic factors are still needed. MicroRNAs (miRs), small endogenous noncoding RNAs, play an essential role in the development and progression of acute leukemia. The aim of the study was to evaluate miR-204 expression in patients with AML at diagnosis and after induction chemotherapy, in comparison to healthy controls. We also investigated, if miR-204 expression correlates with clinical features of AML patients.

Methods

miR-204 expression has been analyzed using RT-PCR in 95 bone marrow specimens from newly diagnosed AML patients in comparison to 20 healthy subject.

Results

We showed down-regulated miR-204 expression in AML patients, which was associated with shorter patients’ survival. Higher expression of miR-204 in patients after induction therapy was correlated with complete remission achieving.

Conclusions

We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this patient population.

【 授权许可】

   
2015 Butrym et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Ustun C, Marcucci G: Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol. 2015, 22:85-91.
• [2]Estey EH: Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol. 2014, 89:1063-81.
• [3]Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, Wang H et al. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer. 2013;12:105. doi:10.1371/journal.pone.0052397.
• [4]Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al.: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010, 20:589-99.
• [5]Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, et al.: Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 2012., 7(12) Article ID e52397
• [6]Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, et al.: MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 2015, 34:35. BioMed Central Full Text
• [7]Yu G, Yao W, Xiao W, Xu H, Li H, Lang B: MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res. 2014, 33:779. BioMed Central Full Text
• [8]Wang C, Zheng X, Shen C, Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012, 31:58. BioMed Central Full Text
• [9]Sümbül AT, Göğebakan B, Ergün S, Yengil E, Batmacı CY, Tonyalı Ö, et al.: miR-204-5p expression in colorectal cancer: an autophagy-associated gene. Tumour Biol 2014, 35:12713-9.
• [10]Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al.: International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-9.
• [11]Cox DR: Regression models and life-tables. J Royal Stat Soc B. 1972, 34:187-220.
• [12]Congdon P: Applied Bayesian modelling. Wiley, Chichester; 2003.
• [13]R Core Team. R: A language and environment for statistical computing. Version 3.0.3. 2014 Vienna: R Foundation for Statistical Computing,. http://www.r-project.org/ webcite
• [14]Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS. Version 1.4.3. 2003. Cambridge: Imperial College School of Medicine & Medical Research Council-Biostatistics Unit, www.mrc-bsu.cam.ac.uk/bugs/winbugs/).
• [15]Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015;S2210-7762(14):00288–9. doi:10.1016/j.cancergen.2014.12.006.
• [16]Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, Mazur G: Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med. 2015, 26:1-8.
• [17]Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L: Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014, 7:3287-92.
• [18]Xia Y, Zhu Y, Ma T, Pan C, Wang J, He Z, et al.: miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC. FEBS Lett 2014, 588:3703-12.
• [19]Wang T, Li F, Tang S: MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett. 2015, 9:967-71.
• [20]Todorova K, Metodiev MV, Metodieva G, Zasheva D, Mincheff M, Hayrabedyan S. miR-204 is Dysregulated in Metastatic Prostate Cancer In Vitro. Mol Carcinog. 2015; doi:10.1002/mc.22263
• [21]Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al.: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012, 107:967-76.
• [22]Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al.: Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012, 130:1036-345.
• [23]Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al.: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc natl Acad Sci USA 2008, 105:3945-50.
• [24]Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, et al.: Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 2013, 12:990-9.